Glonghui, March 14, 丨 Daimo Development Research Report, quoting data from the US Centers for Disease Control and Prevention (CDC), indicates that after more than three years of COVID-19, the influenza season has returned. The current outbreak is mainly H1N1 and H3N2. According to the report, as the main producer of the anti-influenza virus drug “oseltamivir” in the mainland, Dongyang Pharmaceutical's performance is directly driven by the actual spread of influenza and related expectations. By the beginning of March, the company had noticed shortages in several channels and increased production operations to meet demand. The bank raised the company's profit forecast for this year by 19% and next year by 24%. The increase in oseltamivir sales was partially offset by the rehiring of the sales team. Total sales are currently expected to be 6.1 billion yuan this year and 6.7 billion yuan next year. This means the company should return to its all-time high of 2019 sales of 6.2 billion yuan. The rating was upgraded from “in sync with the market” to “increase holdings”, and the target price was raised from HK$7.3 to HK$12. The stock is currently reported at HK$848, with a total market value of HK$7.562 billion.